ProCE Banner Activity

Expert Answers to FAQs on Immune Checkpoint Inhibitors for NSCLC

Clinical Thought
In this commentary, experts answer audience questions from a live satellite symposium at ASCO 2022 on optimal strategies for incorporating ICI-based therapies into the management of early-stage and advanced NSCLC.

Released: August 26, 2022

Expiration: August 25, 2023

No longer available for credit.

Share

Faculty

Julie Brahmer

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Natasha Leighl

Natasha Leighl, MD, MMSC, FRCPC, FASCO

Natasha Leighl, MD, FRCPC, FASCO,
Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Julie Brahmer, MD, MSc, FASCO: consultant/advisor/speaker: Amgen, Blueprint, Bristol-Myers Squibb, Genentech/Roche, Lilly, Janssen, Johnson & Johnson, Merck; researcher: Bristol-Myers Squibb.

Natasha Leighl, MD, MMSC, FRCPC, FASCO

Natasha Leighl, MD, FRCPC, FASCO,
Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

Natasha Leighl, MD, MMsc, FRCPC, FASCO: researcher: Amgen, Array, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Guardant Health, Inivata, MSD, Novartis, Pfizer, Roche, Takeda; consultant/advisor/ speaker: Amgen, Bristol Myers Squibb, GlaxoSmithKline, MSD, Novartis, Puma Biotechnology, Sanofi Genzyme, Takeda.

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS: advisor: Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, NGM Pharmaceuticals, Pfizer, Roche/Genentech, Takeda; data and safety monitoring board: Daiichi Sankyo.